HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
compound 348U87
structure given in first source; antiherpes cpd
Also Known As:
2-actylpyridine 5-((2-chloroanilino)thiocarbonyl)thiocarbonohydrazone; 348 U87; 348U87; BW 348U87; BW-348U87
Networked:
4
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrazines: 379
Hydrazones: 500
compound 348U87: 4
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridines: 88
compound 348U87: 4
Related Diseases
1.
Herpes Simplex
05/01/1993 - "
We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study.
"
04/01/1994 - "
Solar simulator-induced herpes simplex labialis: use in evaluating treatment with acyclovir plus 348U87.
"
01/01/1993 - "
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
"
2.
Infections
05/01/1992 - "
BW 348U87 and ACV are currently being developed as a combination topical therapy for cutaneous herpes infections.
"
01/01/1993 - "
We performed a pilot study of topical combination therapy with 348U87 (3%) and acyclovir (5%) cream for acyclovir-resistant, anogenital HSV infections in ten human immunodeficiency virus (HIV)-infected patients.
"
05/01/1993 - "
Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
"
01/01/1993 - "
In addition, the combination of the ribonucleotide reductase inhibitor 348U87 and acyclovir has synergistic therapeutic effects against infections in mice due to thymidine kinase-deficient, thymidine kinase-altered, and DNA polymerase mutants of HSV.
"
3.
Herpes Labialis (Fever Blister)
04/01/1994 - "
We next evaluated the effects of combined therapy with topical ACV and 348U87, a ribonucleotide reductase inhibitor, begun immediately after UV exposure for the prevention and treatment of herpes labialis.
"
Related Drugs and Biologics
1.
Acyclovir (Aciclovir)
2.
Ribonucleotide Reductases (Ribonucleotide Reductase)
3.
Therapeutic Uses
4.
Thymidine Kinase
5.
DNA-Directed DNA Polymerase (Polymerases, DNA)
Related Therapies and Procedures
1.
Therapeutics